Modeling vaccine trials for hepatitis C
Computational modeling for HCV vaccine trial design and optimal vaccine-based combination interventions
This study is looking at how to create better vaccine trials for hepatitis C, especially for people at high risk, like those who inject drugs, to find the best ways to prevent infections and improve treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Loyola University Chicago NIH-funded |
| Lab location | 1 site (Maywood, United States) |
| Project ID | NIH-10983314 on NIH RePORTER |
What this research studies
This research focuses on developing computational models to design effective vaccine trials for hepatitis C virus (HCV) and to explore optimal combinations of vaccine-based interventions. By analyzing data and simulating various scenarios, the research aims to identify the best strategies for recruiting high-risk populations, such as people who inject drugs, who are significantly affected by HCV. The goal is to enhance the understanding of how vaccines can prevent HCV infections and improve treatment outcomes for those at risk.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk for hepatitis C, particularly those who inject drugs.
Not a fit: Patients who are not at risk for hepatitis C or those who have already been effectively treated for the virus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of an effective vaccine that significantly reduces the incidence of hepatitis C infections.
How similar studies have performed: Previous research has shown promise in vaccine development for viral infections, but this specific approach to HCV vaccine modeling is relatively novel.
Where this research is happening
Maywood, United States
- Loyola University Chicago — Maywood, United States (Active)
Researchers
- Principal investigator: Dahari, Harel — Loyola University Chicago
- Study coordinator: Dahari, Harel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.